The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study.
The aim of this open-label pilot study was to assess the efficacy and safety of the novel anticonvulsant agent, levetiracetam, for the treatment of alcohol dependence. A maximal dose of 2000 mg was administered daily for 10 weeks to alcohol dependent subjects (n = 20). Mean reported ethanol intake declined significantly from 5.3 to 1.7 standard drinks per day. Levetiracetam was well tolerated by most subjects.
Sarid-Segal
Ofra
O
Division of Psychiatry, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Piechniczek-Buczek
Joanna
J
Knapp
Clifford
C
Afshar
Maryam
M
Devine
Eric
E
Sickles
Laurie
L
Uwodukunda
Emma
E
Richambault
Courtney
C
Koplow
Jillian
J
Ciraulo
Domenic
D
D000437:Alcoholism / Q000188:drug therapy* / Q000517:prevention & control; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D010889:Piracetam / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018091:Receptors, AMPA / Q000187:drug effects; D011963:Receptors, GABA-A / Q000187:drug effects; D018009:Receptors, Glycine / Q000187:drug effects
D000927:Anticonvulsants; D018091:Receptors, AMPA; D011963:Receptors, GABA-A; D018009:Receptors, Glycine; D000077287:Levetiracetam; D010889:Piracetam